Patients first

Due to the rapid rise in COVID-19 cases, we are prioritizing critical healthcare resources and reallocating services and support where necessary. Our commitment to your care is steadfast. View our COVID-19 updates, visitor policy and safety information.

Skip Navigation

Monoclonal Antibody Therapy

Monoclonal antibody (mAb) therapy is an available treatment for people recently diagnosed with COVID-19. A monoclonal antibody is a medical product produced in a laboratory. These molecules are designed to act just like the antibodies the body would produce to recover from a disease. The therapy is given by intravenous infusion in an outpatient setting. It should be given as soon as possible after a positive COVID-19 test and within 10 days of symptom onset.

Note: Currently, mAb therapy is not available at the health system’s emergency department. Contact your healthcare provider for a referral.

We offer a variety of appointment types. Learn more or call 913-588-1227 to schedule now.

Who can have monoclonal antibody therapy?

Patients eligible for mAb therapy must meet the following 2 sets of criteria. If you believe you’re eligible, contact your healthcare provider for a referral.

Patients must meet all of the following criteria

  • 12 years of age or older
  • Body weight more than 40 kg (88 lbs.)
  • Confirmed COVID-19 with mild to moderate symptoms*
  • Within 10 days of symptom onset
  • Without increased oxygen requirement from baseline due to COVID-19
  • Not hospitalized currently or within the past 90 days due to COVID-19

If you meet all the above criteria, you must also meet 1 more. See below.

Patients must also meet 1 of the following criteria

Have you received less than 3 vaccine doses?

No: Patients who are fully vaccinated (3 doses of any COVID-19 vaccination) must also meet 1 of the following criteria

  • 65 years of age or older
  • Immunocompromising condition

Yes: Patients who have received less than 3 vaccine doses of any COVID-19 vaccination must also meet 1 of the following criteria

  • 65 years of age or older
  • Body mass index (BMI) >35 or >85th percentile for children under 18
  • Pregnant
  • Active cancer
  • Stem cell transplant
  • Solid organ transplant
  • HIV with CD4 count less than 300
  • Sickle cell disease
  • Immunocompromising condition
  • Stage IV CKD or greater
  • Diabetes with HBA1C greater than 8.5%
  • Liver cirrhosis
  • Neurodevelopmental disorders or other severe genetic/metabolic disorders and medical-related technological dependence
  • Congenital heart disease with ongoing symptoms
  • CF or non-CF bronchiectasis with FEV1 < 60%
  • Be 55 years of age or older with 1 of the following
    • Underlying restrictive/obstructive lung disease with FVC or FEV1 less than 60% predicted
    • Pulmonary hypertension on vasodilator therapy
    • Congestive heart failure
  • Be 18 years of age or younger with chronic respiratory disease requiring daily medication

*Symptoms must include 1 or more of the following: fever, cough, sore throat, malaise, headache, GI symptoms, myalgias, dyspnea on exertion worse than baseline or change of sense of taste or smell